Name: An Open-Label, Multicenter, Phase IIIb Study of Patients with Urinary Tract Carcinoma (UTC) (STRONG): Final Analysis for Fixed-Dose Durvalumab Monotherapy (Module A)
Uploaded: 2021-02-19T00:00:00+00:00
Description: Bladder Cancer: Guru Sonpavde, MD details STRONG study results presented at ASCO #GU21? that find fixed-dose durvalumab monotherapy safe in patients previously treated for urinary tract carcinoma. Abstract 429

Bladder Cancer: Guru Sonpavde, MD details STRONG study results presented at ASCO #GU21? that find fixed-dose durvalumab monotherapy safe in patients previously treated for urinary tract carcinoma. Abstract 429

Related Presenters

Guru P. Sonpavde, MD

Medical Oncology

Guru P. Sonpavde, MD was the director of the bladder cancer program at Dana-Farber Cancer Institute and was on the faculty of Harvard Medical School. He completed his medical oncology fellowship at Indiana University. His primary focus ...

View Profile